Impact of High Loading Dose of Atorvastatin in Diabetic Patients with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial

Cardiovascular Therapeutics

Volumn 33, Issue 2, 2015, Pages 35-41

  Shehata, Mohamed ^a   Hamza, Mohamed ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Contrast induced nephropathy; Coronary intervention; Diabetes mellitus; Statins

Indexed keywords

ATORVASTATIN; CREATININE; IOPROMIDE; POTASSIUM; SODIUM; BIOLOGICAL MARKER; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; ANGIOCARDIOGRAPHY; BLOOD; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHIES; EGYPT; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROTECTION; RADIOGRAPHY; RISK FACTOR; TIME; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ATORVASTATIN CALCIUM; BIOMARKERS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CREATININE; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; EGYPT; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925352388     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12108     Document Type: Article

References (30)

1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419-1428.
2. Gauthaman K, Manasi N, Bongso A. Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol 2009;157:962-973.
3. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
4. Briguori C, Visconti G, Focaccio A, et al. Novel Approaches for Preventing or Limiting Events (NAPLES) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-2163.
5. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, Sciascio G. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-285.
6. Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. Am J Cardiol 2011;108:1-7.
7. Jo S-H, Koo B-K, Park J-S, et al. Prevention of Radiocontrast Medium Induced Nephropathy Using Short-Term High-Dose Simvastatin in Patients with Renal Insufficiency Undergoing Coronary Angiography (PROMISS) trial: a randomized controlled study. Am Heart J 2008;155:499. e1-e8.
8. Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010;105:288-292.
9. ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619.
10. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
11. Ozhan H, Erden I, Ordu S, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010;61:711-714.
12. Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging 2013;4:811-820.
13. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 2008;49:646-657.
14. Stacul F, Van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011;21:2527-2541.
15. Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc 2009;84:170-179.
16. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-651.
17. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
18. Tucci Junior S, Molina CA, Cassini MF, Leal DM, Schineider CA, Martins AC. Lovastatin protects mithochondrial and renal function in kidney ischemia-reperfusion in rats. Acta Cir Bras 2012;27:477-481.
19. Ellis JH, Cohan RH. Prevention of contrast-induced nephropathy: an overview. Radiol Clin North Am 2009;47:801-811.
20. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003;58:336-341.
21. Yenicerioglu Y, Yilmaz O, Sarioglu S, Ormen M, Akan P, Celik A, Camsari T. Effects of N-acetylcysteine on radiocontrast nephropathy in rats. Scand J Urol Nephrol 2006;40:63-69.
22. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents-a new use for an old drug. N Engl J Med 2000;343:210-212.
23. ESC. Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
24. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
25. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999;33:403-411.
26. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol 2011;33:344-351.
27. Cao S, Wang P, Cui K, Zhang L, Hou Y. Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress. Nan Fang Yi Ke Da Xue Xue Bao 2012;32:1600-1602.
28. Quintavalle C, Fiore D, De Micco F, Zhang L, Hou Y. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012;126:3008-3016.
29. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 2014;63:71-79.
30. Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:519-524.